文献速递眼底病与葡萄膜炎

社区层面差异与医保B部分抗VEGF药物标签内与标签外使用及支出

Community-Level Variation in On-Label Versus Off-Label Anti-VEGF Use and Medicare Part B Spending.
PubMed 文献 · Retina · 2026-07-21

PURPOSE: To examine whether community-level sociodemographic characteristics are associated with differences in on-label versus off-label anti-VEGF agent use under Medicare Part B and to estimate differential spending attributable to variation in community-level agent mix.…

要点

  • 社区中Medicare年龄人口比例每增10个百分点,标签内使用比例增6.1个百分点。
  • 社区中非常低收入居民比例每增10个百分点,标签内使用比例降3.1个百分点。

核心结论

  • 尽管报销标准统一,Medicare Part B中标签内抗VEGF药物使用存在显著的社区层面差异。
  • 这些差异导致数十亿美元的支出差别,并引发可及性、公平性和价值医疗问题。

研究设计与样本

  • 基于2013-2023年Medicare Part B索赔数据,识别开具标签内或标签外抗VEGF注射的提供者。
  • 为每个提供者年度生成15分钟车程服务区,叠加美国人口普查区及ACS社会经济数据,进行多变量逻辑回归和反事实模拟。

主要发现

  • 标签内使用比例较高与社区中Medicare年龄人口比例(AME每增10个百分点:+6.1个百分点,95%CI 3.1-9.0)、黑人/非裔美国人比例(+2.4,95%CI 1.5-3.3)和大学教育居民比例(+3.2,95%CI 1.9-4.5)相关。
  • 标签内使用比例较低与非常低收入居民比例相关(AME:-3.1,95%CI -5.3至-0.8),而西班牙裔/拉丁裔比例(+0.4,95%CI -0.6-1.3)和人口密度(每翻倍AME:+0.8,95%CI -0.2-1.8)无关联。

关键数值与推荐

  • 标签内抗VEGF药物包括阿柏西普、雷珠单抗、法瑞西单抗、布罗鲁单抗及其生物类似药;标签外药物为贝伐珠单抗。
  • 社区中Medicare年龄人口比例每增加10个百分点,标签内使用比例调整边际效应为+6.1个百分点(95%CI 3.1-9.0)。
  • 社区中黑人/非裔美国人比例每增加10个百分点,标签内使用比例调整边际效应为+2.4(95%CI 1.5-3.3)。
  • 社区中大学教育居民比例每增加10个百分点,标签内使用比例调整边际效应为+3.2(95%CI 1.9-4.5)。
  • 社区中非常低收入居民比例每增加10个百分点,标签内使用比例调整边际效应为-3.1(95%CI -5.3至-0.8)。

临床怎么用

  • 临床医生应意识到社区社会经济特征可能影响抗VEGF药物选择,需关注标签外使用的公平性。
  • 在价值医疗和医保支付背景下,优化药物组合可节约支出,但需平衡可及性与个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine whether community-level sociodemographic characteristics are associated with differences in on-label versus off-label anti-VEGF agent use under Medicare Part B and to estimate differential spending attributable to variation in community-level agent mix. METHODS: Part B claims data (2013-2023) were analyzed to identify providers billing for on-label (aflibercept, ranibizumab, faricimab, brolucizumab, and biosimilars) or off-label (bevacizumab) anti-VEGF injections. For each provider year, 15-min drive-time service areas were generated and overlaid on U.S. Census tracts enriched with American Community Survey-derived sociodemographic data. Community-level profiles were generated through population-weighted aggregation of tracts within each service area. Multivariable logistic regression estimated adjusted marginal effects (AMEs) of sociodemographic variables on on-label anti-VEGF proportion. Counterfactual simulations estimated Part B spending under alternative community-level agent mix scenarios. RESULTS: From 2013-2023, 5,178 providers billed Part B for 34.5 million anti-VEGF injections. Higher on-label use was associated with greater community-level proportions of Medicare-aged (AME per 10-percentage-point [pp] increase: +6.1 pp [95% CI: 3.1-9.0]), Black/African American (+2.4 [1.5-3.3]), and college-educated residents (+3.2 [1.9-4.5]). An inverse association was observed for proportion very low-income residents (-3.1 [-5.3 to -0.8]), while no association was observed for proportion Hispanic/Latino residents (+0.4 [-0.6-1.3]) or population density (AME per doubling: +0.8 [-0.2-1.8]). Equalizing anti-VEGF mix to that of the highest-poverty quartile would have resulted in approximately $4.2 billion lower spending. CONCLUSIONS: Despite uniform reimbursement, significant community-level differences exist in on-label anti-VEGF use within Medicare Part B. These gradients produce billions of dollars in differential spending and raise questions of access, equity, and value-based care.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Franco JJ, Song A, Pan WW, et al. Community-Level Variation in On-Label Versus Off-Label Anti-VEGF Use and Medicare Part B Spending. Retina. 2026. PMID: 42479493. doi:10.1097/IAE.0000000000004920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。